Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Bavarian Nordic A/S
Beijing Advaccine Biotechnology Company Ltd
IDBiologics Inc
Sigmovir Biosystems Inc
Visterra Inc
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles
Monoclol Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-3D3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-RSV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2018: Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
Mar 06, 2018: Bavarian Nordic Announces Additiol Positive Data from a Phase 2 Study of its Universal RSV Vaccine
Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine
Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic’s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV
Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine
Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine
Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At Intertiol RSV Symposium
May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Bavarian Nordic A/S, H1 2020
Pipeline by Beijing Advaccine Biotechnology Company Ltd, H1 2020
Pipeline by IDBiologics Inc, H1 2020
Pipeline by Sigmovir Biosystems Inc, H1 2020
Pipeline by Visterra Inc, H1 2020
Dormant Projects, H1 2020